Insights Center
Thought leadership, news, events — you will find them all here, right at your fingertips. We’ve consolidated the firm’s most popular content in one, easy to search location. Enter a key word or phrase to find pertinent blog posts, articles, press releases, and upcoming events.
Mintz Direct
Mintz Viewpoints
Showing 7409 - 7416 of 12030 results
False Labeling Lawsuits Get Hung Up On Faulty Damages Models
January 16, 2017| Blog| Viewpoint
Can Employers Include Class/Collective Action Waivers in Arbitration Agreements? Supreme Court to Decide.
January 16, 2017| Blog| Viewpoint
FTC Takes Action Against D-Link for Deceptive Practices Endangering the IoT
January 13, 2017| Blog| Viewpoint
Health Care Enforcement Review And 2017 Outlook: Part 1
January 13, 2017| News
FDA Sticks to Its Naming Plan for Biologics and Biosimilars
January 13, 2017| News
FDA Finalizes Tobacco Product Intended Use Rules, Under a Risk of Rescission by Congress
January 12, 2017| Blog| Viewpoint
Pizza! Pizza!: Little Caesar’s Repeated Term Slogans Are Not a “Family of Marks”
January 12, 2017| Blog| Viewpoint
When An Arbitration Clause Sounds Permissive But Is Not -- Does "May" Really Mean "Must"?
January 12, 2017| Blog| Viewpoint
News & Press Releases
San Francisco Business Times featured Mintz’s new office lease in San Francisco at 525 Market St. The firm will be increasing its footprint in downtown by 50% to 29,000 square feet on a whole single floor with the new space.
Mintz advised the underwriters in connection with a $230 million public offering by Cogent Biosciences, Inc. of 25,555,556 shares of common stock, which includes 3,333,333 shares issued pursuant to the exercise in full by the underwriters of their option to purchase additional shares of common stock, offered at a public offering price of $9.00 per share. The aggregate gross proceeds to Cogent from this offering were approximately $230 million, including proceeds from the exercise in full by the underwriters of the option to purchase additional shares, before deducting underwriting discounts and commissions and other offering expenses.
Mintz advised the underwriters in connection with a $200 million public offering by Soleno Therapeutics, Inc. of 2,352,941 shares of its common stock at a price to the public of $85.00 per share. The gross proceeds to Soleno from the offering were approximately $200 million before deducting underwriting discounts and commissions and other offering expenses. In addition, Soleno granted the underwriters a 30-day option to purchase up to an additional 352,941 shares of its common stock at the public offering price.
Events
Mintz x The Engine: Supercharging Your IP Strategy with Trade Secrets
The Engine, 750 Main St. Cambridge, MA 02139
Podcasts
Mintz On Air: Practical Policies — A Private Equity Non-Compete Primer
July 15, 2025| Podcast|
Health Law Diagnosed – Best Practices for Communicating with the FDA
July 9, 2025| Podcast|